ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.6086
0.00%
Brent Oil
83.76
0.00%
Bitcoin
67,078.44
0.21%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Silence Therapeutics PLC (SLN)

  7. Silence Therapeutics PLC (SLN) Noticias

SLN

Silence Therapeutics (SLN)

Silence Therapeutics PLC
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:SLN
FechaHoraFuenteTítuloSímboloCompañía
17/05/202416:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SLNSilence Therapeutics PLC
16/05/202407:30Business WireSilence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline ProgressNASDAQ:SLNSilence Therapeutics PLC
14/05/202415:27Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SLNSilence Therapeutics PLC
08/05/202416:14Edgar (US Regulatory)Form DEL AM - Delaying amendmentNASDAQ:SLNSilence Therapeutics PLC
30/04/202407:30Business WireSilence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor ConferenceNASDAQ:SLNSilence Therapeutics PLC
29/04/202407:30Business WireSilence Therapeutics Announces Retirement of Alistair Gray from Board of DirectorsNASDAQ:SLNSilence Therapeutics PLC
08/04/202410:48Business WireSilence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)NASDAQ:SLNSilence Therapeutics PLC
13/03/202406:05Business WireSilence Therapeutics Reports Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:SLNSilence Therapeutics PLC
13/03/202406:03IH Market NewsMixed Futures Amidst Quiet Economic Schedule; Oil Prices ClimbNASDAQ:SLNSilence Therapeutics PLC
13/03/202406:00Business WireSilence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)NASDAQ:SLNSilence Therapeutics PLC
28/02/202407:00Business WireSilence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024NASDAQ:SLNSilence Therapeutics PLC
23/02/202407:00Business WireSilence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 TrialNASDAQ:SLNSilence Therapeutics PLC
14/02/202408:54Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SLNSilence Therapeutics PLC
05/02/202407:00Business WireSilence Therapeutics Announces Oversubscribed $120 Million Private PlacementNASDAQ:SLNSilence Therapeutics PLC
31/01/202406:00Business WireSilence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:SLNSilence Therapeutics PLC
01/12/202306:00Business WireSilence Therapeutics Strengthens Executive Leadership Team with Key AppointmentsNASDAQ:SLNSilence Therapeutics PLC
14/11/202306:00Business WireSilence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial ResultsNASDAQ:SLNSilence Therapeutics PLC
08/11/202306:00Business WireSilence Therapeutics to Present at Jefferies London Healthcare ConferenceNASDAQ:SLNSilence Therapeutics PLC
01/11/202306:00Business WireSilence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular DiseaseNASDAQ:SLNSilence Therapeutics PLC
26/09/202306:00Business WireSilence Therapeutics to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines ConferenceNASDAQ:SLNSilence Therapeutics PLC
06/09/202306:00Business WireSilence Therapeutics to Participate in September Investor ConferencesNASDAQ:SLNSilence Therapeutics PLC
29/08/202315:01Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:SLNSilence Therapeutics PLC
16/08/202306:00Business WireSilence Therapeutics Reports Second Quarter 2023 ResultsNASDAQ:SLNSilence Therapeutics PLC
01/08/202315:31Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SLNSilence Therapeutics PLC
11/07/202306:00Business WireSilence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma CollaborationNASDAQ:SLNSilence Therapeutics PLC
31/05/202306:00Business WireSilence Therapeutics to Present at the Jefferies Healthcare ConferenceNASDAQ:SLNSilence Therapeutics PLC
16/05/202315:02Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:SLNSilence Therapeutics PLC
16/05/202315:00Business WireSilence Therapeutics Reports First Quarter 2023 ResultsNASDAQ:SLNSilence Therapeutics PLC
04/05/202306:00Business WireSilence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca CollaborationNASDAQ:SLNSilence Therapeutics PLC
01/05/202306:00Business WireSilence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease EventsNASDAQ:SLNSilence Therapeutics PLC
 Showing the most relevant articles for your search:NASDAQ:SLN

Su Consulta Reciente

COIN
MULTIETH
Multichain
EU
E952S
E952S
TSXV
ELS
El Tigre Silver Corp.
BOV
VISA34M
Visa
TSXV
VZLA
Vizsla Silver
USOTC
HWKDD
Hawkeye Gold and Diamond (PK)
BIT
F17365
Vontobel Financial Produ...
EU
ADAVE
Valour Cardano
BMF
DOLQ17
NASDAQ
AAXGUXX
Citigroup Global Markets...
USOTC
CMXC
Cell MedX (PK)
AMEX
HYMU
BlackRock High Yield Mun...
BIT
NSCIT2752813
AIIB
LSE
46IV
Thames W.u. 41
BOV
BIET39
BlackRock Institutional ...
TSXV
COCO
Coast Copper
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados